---
title: "Immunome | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 0"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/264730351.md"
datetime: "2025-11-06T22:05:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264730351.md)
  - [en](https://longbridge.com/en/news/264730351.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264730351.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/264730351.md) | [繁體中文](https://longbridge.com/zh-HK/news/264730351.md)


# Immunome | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0, missing the estimate of USD 727.27 K.

EPS: As of FY2025 Q3, the actual value is USD -0.65, missing the estimate of USD -0.5759.

EBIT: As of FY2025 Q3, the actual value is USD -62.82 M.

### Segment Revenue

-   **Collaboration Revenue**: For the nine months ended September 30, 2025, collaboration revenue was $6.941 million, compared to $6.303 million for the same period in 2024, reflecting an increase of $0.638 million.

### Operational Metrics

-   **Net Loss**: The net loss for the nine months ended September 30, 2025, was - $142.494 million, compared to - $212.714 million for the same period in 2024, showing a reduction in net loss by $70.220 million.
-   **Research and Development Expenses**: Increased by $44.864 million, from $81.652 million for the nine months ended September 30, 2024, to $126.516 million for the same period in 2025.
-   **General and Administrative Expenses**: Increased by $9.168 million, from $22.509 million for the nine months ended September 30, 2024, to $31.677 million for the same period in 2025.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the nine months ended September 30, 2025, net cash used in operating activities was - $142.966 million, compared to - $68.734 million for the same period in 2024.
-   **Net Cash Provided by Investing Activities**: For the nine months ended September 30, 2025, net cash provided by investing activities was $64.802 million, compared to net cash used of - $94.821 million for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: For the nine months ended September 30, 2025, net cash provided by financing activities was $207.562 million, compared to $220.444 million for the same period in 2024.

### Unique Metrics

-   **Share-Based Compensation Expense**: Total share-based compensation expense for the nine months ended September 30, 2025, was $17.797 million, compared to $10.278 million for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: Immunome, Inc. plans to continue advancing its pipeline, which includes three clinical assets and three preclinical assets. The company expects to report topline data from the Phase 3 trial of Varegacestat in the second half of 2025 and plans to initiate a Phase 1 trial for IM-3050 in early 2026.
-   **Non-Core Business**: The company is investing in discovery efforts to expand its pipeline, focusing on additional ADC programs and developing a diverse pipeline of ADCs.

### 相关股票

- [Immunome (IMNM.US)](https://longbridge.com/zh-CN/quote/IMNM.US.md)

## 相关资讯与研究

- [Immunome President, CEO Purchased Shares Worth Over $500K](https://longbridge.com/zh-CN/news/281176937.md)
- [Tuesday 3/31 Insider Buying Report: NAVN, IMNM](https://longbridge.com/zh-CN/news/281209986.md)
- [Western Copper and Gold reports FY results](https://longbridge.com/zh-CN/news/280777357.md)
- [Cintas (CTAS) Valuation Check After Q3 Results And Higher Fiscal 2026 Guidance](https://longbridge.com/zh-CN/news/281225115.md)
- [Nike Delivers Q3 Earnings Beat As Turnaround Progresses, Shares Slide](https://longbridge.com/zh-CN/news/281243092.md)